Assessment of financial toxicity in patients with cancer in Slovenia
Supportive Care in Cancer · 2025
DOI: 10.1007/s00520-025-09591-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Katja Vöröš und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Neoplasms, Health Expenditures, Financial Stress, Cost of Illness. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian Research And Innovation Agency (ARIS).
Abstract (Originalsprache)
Purpose
The aim of this study was to assess the extent of financial toxicity in patients with cancer in Slovenia, measured as perceived financial strain and out-of-pocket expenditures.
Methods
The prospective, cross-sectional study was done at Institute of Oncology Ljubljana from June to October 2023. A newly created individual questionnaire was utilized to obtain data on financial toxicity. Patients completed the questionnaire either on paper or online, with or without the assistance of a researcher. The statistical analysis was based on descriptive and inferential statistics.
Results
A total of 901 surveys were disseminated, of which 659 were returned, corresponding to a response rate of 73%. Most patients had compulsory health insurance and were diagnosed in the public healthcare system. Following a cancer diagnosis, 178 (27%) patients reported a decline in financial satisfaction (subjective assessment), while 150 (22.7%) patients observed a change in their financial capability (objective assessment). Younger patients ( p < 0.001), female patients ( p < 0.004), patients with lower net household income ( p < 0.001), and patients who were employed before the diagnosis ( p < 0.001) were at a greater risk for financial toxicity. Patients with breast cancer and colorectal, endometrial, skin (including melanoma), esophageal, stomach, kidney, bladder cancers, and lymphoma had higher self-reported subjective and objective financial toxicity than patients with prostate, lung, and head and neck cancer.
Conclusion
This article represents the first comprehensive assessment of financial toxicity among patients with cancer in Slovenia, using perceived financial strain and out-of-pocket expenditures. Most patients reported no significant out-of-pocket costs for the treatment they received. About a quarter of patients with cancer experience financial difficulties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- School of Economics and Business, University of Ljubljana, Ljubljana, Slovenia.
- Division of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
- Division of Radiotherapy, Institute of Oncology Ljubljana, Zaloska Cesta 2, 1000, Ljubljana, Slovenia.
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. iratosa@onko-i.si.
- Division of Radiotherapy, Institute of Oncology Ljubljana, Zaloska Cesta 2, 1000, Ljubljana, Slovenia. iratosa@onko-i.si.
Förderung
- Slovenian Research And Innovation Agency (ARIS)
Zitieren
APA
Vöröš, K., Skubic, M., Bavdaž, M., Došenović Bonča, P., Perhavec, A., Redek, T., Zobec Logar, H. B., & Ratoša, I. (2025). Assessment of financial toxicity in patients with cancer in Slovenia. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-09591-7
Vancouver
Vöröš K, Skubic M, Bavdaž M, Došenović Bonča P, Perhavec A, Redek T, et al. Assessment of financial toxicity in patients with cancer in Slovenia. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-09591-7
BibTeX
@article{Vr2025,
author = {Vöröš, Katja and Skubic, Marjeta and Bavdaž, Mojca and Došenović Bonča, Petra and Perhavec, Andraž and Redek, Tjaša and Zobec Logar, Helena Barbara and Ratoša, Ivica},
title = {Assessment of financial toxicity in patients with cancer in Slovenia},
journal = {Supportive Care in Cancer},
year = {2025},
doi = {10.1007/s00520-025-09591-7}
}
EUVIMED